1. Home
  2. |Insights
  3. |'A Higher Ethical Obligation?' State Revenue Execs Speak Out in Crowell's Conversations

'A Higher Ethical Obligation?' State Revenue Execs Speak Out in Crowell's Conversations

Client Alert | 1 min read | 01.15.14

Crowell & Moring's state tax team traveled from coast to coast in 2013 to introduce the corporate world to 10 of the country's top state tax decision makers. In Crowell's Conversations – a monthly column appearing in Bloomberg BNA's Weekly State Tax Report – we bring you timely and candid observations from different states' commissioners and their counsel. The revenue executives discussed everything from litigation and policy-making to resources and technology to their personal careers. While the questions and responses differed in each column, a common theme last year was the core belief that the states have a higher ethical obligation to get to the "right" answer rather than to collect the most revenue. We hope you have enjoyed getting to know our friends in the state revenue departments, and we look forward to bringing you more great interviews in 2014. Below are links to the first nine interviews. 

  • Michael Bryan, Director of the New Jersey Division of Taxation (December 6, 2013).

  • Jozel Brunett, California Franchise Tax Board Chief Counsel (November 8, 2013).

  • Julie Magee, Commissioner of the Alabama Department of Revenue (August 30, 2013).

  • Tim Barfield, Secretary at the Louisiana Department of Revenue (July 19, 2013).

  • Barbara Brohl, Executive Director and John Vecchiarelli, Senior Director of the Colorado Department of Revenue (June 21, 2013).

  • Marshall Stranburg, Executive Director at the Florida Department of Revenue (May 3, 2013).

  • Peter Franchot, Comptroller of Maryland (April 12, 2013).

  • Milton Kimpson, General Counsel to the South Carolina Department of Revenue (March 15, 2013).

  • Alan Levine, Chief Counsel With the District of Columbia's Office of Tax and Revenue (February 15, 2013).

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...